Teva Pharmaceutical Industries Limited (NYSE:TEVA) received a $39.00 price objective from investment analysts at Credit Suisse Group in a research report issued on Thursday. The firm currently has a “buy” rating on the stock. Credit Suisse Group’s price objective indicates a potential upside of 89.32% from the company’s previous close.

A number of other equities analysts have also issued reports on the company. Oppenheimer Holdings, Inc. lowered Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and set a $41.00 target price for the company. in a research note on Thursday. Mizuho reiterated a “hold” rating and set a $30.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Jefferies Group LLC reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, July 25th. Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective for the company in a research note on Monday, July 24th. Finally, Zacks Investment Research upgraded Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. One analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $39.81.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 13.26% on Thursday, hitting $20.60. The stock had a trading volume of 93,317,085 shares. The firm has a market cap of $20.93 billion, a PE ratio of 264.10 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a 52-week low of $20.41 and a 52-week high of $55.45. The company has a 50-day moving average price of $32.05 and a 200 day moving average price of $32.28. Teva Pharmaceutical Industries Limited also was the recipient of some unusual options trading on Thursday. Stock investors bought 66,716 put options on the stock. This represents an increase of approximately 864% compared to the average daily volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.18% and a negative net margin of 25.18%. The business’s revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the business earned $1.25 EPS. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.65 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/06/credit-suisse-group-analysts-give-teva-pharmaceutical-industries-limited-teva-a-39-00-price-target.html.

Institutional investors have recently added to or reduced their stakes in the stock. Cribstone Capital Management LLC increased its position in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC bought a new position in Teva Pharmaceutical Industries Limited during the first quarter valued at about $123,000. Finally, Sterling Investment Advisors Ltd. increased its position in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares in the last quarter. Institutional investors own 56.20% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.